Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499395 · ClinicalTrials.gov registry record · NA
Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer
A NA study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00499395 is a NA study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 4 participants.
The verdict
NCT00499395, a NA study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET imaging, may be effective in detecting residual disease after radiofrequency ablation of liver metastases in patients with colorectal cancer. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works for early detection of residual disease in patients undergoing radiofrequency ablation of liver metastases from colorectal cancer.
Interventions
- PROCEDURE positron emission tomography
- PROCEDURE radiofrequency ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499395
The ClinicalTrials.gov registry entry for NCT00499395 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which positron emission tomography is the first listed.
NCT00499395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499395 about?
NCT00499395 is a clinical study titled "Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer". RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET imaging, may be effective in detecting residual disease after radiofrequency ablation of liver metastases in patients with colorectal cancer. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well ...
What is the current status of trial NCT00499395?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2005-07. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00499395?
The interventions under investigation include: positron emission tomography (PROCEDURE), radiofrequency ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00499395?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.